Cambridge

Cambridge


In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.

Colleagues from our biologics research and development arm, MedImmune (formerly Cambridge Antibody Technology), have long been based in Cambridge. Currently about 500 people are based at Granta Park. MedImmune is known as a world-leader in protein engineering and biologics drug development. In 2014, an additional 400 AstraZeneca employees have begun working at interim Cambridge locations, while the planning and building of our new site progresses. In addition to Granta Park, our interim locations include facilities at Melbourn Science Park and the Cambridge Science Park.

Our move to Cambridge reflects its global importance as a centre for biopharmaceutical research and development. The city offers invaluable access to world-leading scientific expertise and provides excellent opportunities for collaboration with renowned academic research institutions, pre-eminent hospitals and cutting-edge biotech companies.

Our focus on science

The Cambridge site will become our largest centre for oncology research worldwide. Beyond cancer research, our R&D will focus on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. The site will bring together our small molecule and biologics R&D, opening up opportunities to exploit the promise of small and large molecule combinations. Additionally, we will have medicinal chemistry, high-throughput screening and cellular and molecular biology, as well as clinical development and pre-clinical research capabilities located on the site.

As our largest oncology research centre, the new site will also include a purpose-designed rodent facility principally to support our early stage cancer research. Animal studies are a vital part of the research process, and are required by regulators before they approve a new medicine to be tested in humans during clinical trials.

For further details on our research ethics in relation to animals, please visit: http://www.astrazeneca.com/Responsibility/Research-ethics/Animal-research

In the Community

AstraZeneca and MedImmune provide community support to charities and other not-for-profit organisations, with a focus on enhancing science education and improving healthcare. In particular, we support educational events for young people in science and encourage our employees to volunteer as part of a national STEM (Science, Technology, Engineering and Mathematics) Ambassador Programme, inspiring science projects in primary and secondary schools. We also offer work experience placements for students interested in a future career in the industry.

For more information on our community support activity, please follow this link: http://www.astrazeneca.co.uk/community-support

A Great Place to Work

Our plans in Cambridge include recruiting scientists to Cambridge from around the world.

If you would like to know more about job opportunities in Cambridge please visit our careers portal: https://cambridge-jobs.astrazeneca.com.
 

Designs for new Cambridge site

To view the proposed designs of our new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.

Cambs RH thumb img

Read full press release

View photo library


Careers opportunities

If you would like to know more about job opportunities in Cambridge please visit our careers portal.


Community support

AstraZeneca is committed to acting responsibly with regard to its economic, social and environmental impact on society

Read more about our community support activity


Research news

For more information on our latest research news, please click here.


MedImmune

For information on our biologics arm, please visit the MedImmune website



MedImmune was acquired by AstraZeneca in 2007. This enabled us to expand our biologics capabilities and create one of the world’s largest biologics pipelines.